Welcome to our dedicated page for LakeShore Biopharma Co. Warrants SEC filings (Ticker: LSBPW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for LSBPW provides access to regulatory documents associated with LakeShore Biopharma Co., Ltd., a foreign issuer that reports under the Securities Exchange Act of 1934. The company identifies itself as a Form 20-F filer, meaning its annual reports follow the format used by non‑U.S. companies listed in U.S. markets.
Among the filings is a Form 6-K current report that lists an exhibit titled "Press Release - LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting." This filing documents a significant change in the company’s trading status, noting that its securities were delisted from Nasdaq and that it announced a transition to an over‑the‑counter (OTC) market. Such filings are central for understanding the historical and regulatory context of the LSBPW ticker.
On this page, users can review forms like Form 20-F for annual disclosures and Form 6-K for interim updates, including exhibits that describe events such as listing changes. These documents help clarify how LakeShore Biopharma presents its operations, risks, and market status to regulators and investors.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy reports, highlight important events such as delistings and market transitions, and make it easier to navigate complex foreign issuer disclosures. Real-time updates from EDGAR ensure that new 6-K and 20-F submissions related to LSBPW appear promptly, while AI insights help users focus on the sections that matter most for understanding the company’s regulatory history.
LakeShore Biopharma Co., Ltd has called an extraordinary general meeting of shareholders for February 12, 2026 at 11 a.m. (Beijing time) in Beijing. Shareholders will be asked to consider and vote on authorizing and approving a previously announced Agreement and Plan of Merger with Oceanpine Skyline Inc. and its subsidiary Oceanpine Merger Sub Inc., along with a related Cayman Islands plan of merger.
At the effective time of the merger, Merger Sub will merge into LakeShore Biopharma, which will survive as a wholly owned subsidiary of Oceanpine Skyline Inc. If completed, the merger will result in LakeShore Biopharma becoming a privately held company, and its ordinary shares and warrants will no longer be quoted on any public marketplace, including the OTC Pink tier, and will cease to be registered under the U.S. securities laws.
The board of directors, following a unanimous recommendation from a special committee of independent directors, has approved the merger documents and resolved to recommend that shareholders vote FOR the proposals. Shareholders of record as of 5 p.m. Cayman Islands time on January 16, 2026 are entitled to attend and vote at the meeting. Additional details are provided in the Schedule 13E-3 transaction statement and definitive proxy statement filed with the SEC.
Amendment to Schedule 13D reporting that a consortium led by Oceanpine Investment, Oceanpine Capital and Crystal Investment has proposed a potential acquisition of all outstanding ordinary shares of LakeShore Biopharma Co., Ltd. The Revised Proposal values each ordinary share at US$0.86 in cash. Crystal Investment currently holds 21,021,332 shares (51.0%) based on 41,212,693 shares outstanding as of June 30, 2025. Oceanpine-held positions total 462,760 shares (1.1%), comprising 410,560 held by Oceanpine Investment and 52,200 by Oceanpine Capital.
The Consortium entered a Consortium Agreement providing for cooperative negotiation, exclusive collaboration among members for up to 24 months, and anticipated contributions of cash or shares to an acquisition vehicle. The Reporting Persons estimate approximately US$20,000,000 will be expended to acquire the publicly held shares at the Revised Proposal price. If consummated, the Proposed Transaction could result in delisting and termination of registration of the Ordinary Shares.
